All INCY Content

Incyte Corporation (INCY) Q1 2026 Earnings Call

Incyte Corporation (NASDAQ: INCY) Q1 2026 Earnings Conference

April 9, 20261 min read

Incyte Corporation (INCY) Q1 2026 Earnings Announcement

Incyte Corporation (NASDAQ: INCY) Q1 2026 Earnings Announcement

April 9, 20261 min read

Incyte Corporation (INCY) Sec Form 8K

Incyte Corporation (NASDAQ: INCY) Sec Form 8K

March 31, 20261 min read

Incyte Corporation (INCY) Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting

Incyte Corporation (NASDAQ: INCY) FY 2026 Other Release

March 29, 20261 min read

Incyte Corporation (INCY) Sec Form 8K

Incyte Corporation (NASDAQ: INCY) Sec Form 8K

March 28, 20261 min read

Incyte Corporation (INCY) Incyte Announces Executive Leadership Appointments

Incyte Corporation (NASDAQ: INCY) FY 2026 Management Update

March 25, 20261 min read

Incyte Corporation (INCY) Incyte to Highlight Late-Breaking Hidradenitis Suppurativa Data at the 2026 American Academy of Dermatology (AAD) Annual Meeting

Incyte Corporation (NASDAQ: INCY) FY 2026 Other Release

March 20, 20261 min read

Incyte Corporation (INCY) Q4 2025 Earnings Call Transcript

Incyte Corporation (NASDAQ: INCY) Q4 2025 Earnings Call dated Feb. 10, 2026 Corporate Participants: Alexis Smith — Vice President &...

March 10, 202649 min read

Incyte Corporation (INCY) Sec Form 8K

Incyte Corporation (NASDAQ: INCY) Sec Form 8K

March 7, 20261 min read

Incyte Corporation (INCY) Incyte Announces the European Commission Approval of Zynyz® (retifanlimab) for the First-Line Treatment of Advanced Squamous Cell Carcinoma of the Anal Canal (SCAC)

Incyte Corporation (NASDAQ: INCY) FY 2026 Other Release

March 6, 20261 min read